Akebia Therapeutics Reports Positive Results of Vadadustat in P-III J01 & J03 Studies for Anemia Due to Chronic Kidney Disease (CKD) in Japan
- The two P-III J01 & J03 studies involve assessing of Vadadustat vs darbepoetin alfa in 304 & 323 Japanese patients (non- dialysis dependent & dialysis dependent) with anemia due to CKD @52wks.
- The P-III J01 & J03 studies result: met its 1EPs; @20 &24 wks. mean Hb level (11.66 g/dL & 10.61 g/dL vs 11.93 g/dL & 10.65 g/dL); SAEs (13.9% & 13.0% vs 14.4% & 10.6%)
- Vadadustat is an oral HIF prolyl hydroxylase inhibitor- co-developed by Akebia & MTPC with its expected NDA filing in Japan in 2019
Ref: Akebia | Image: Contract Pharma
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com